1-[2-(ethylamino)ethyl]-3,5-dimethylpyrazole | 167960-75-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-[2-(ethylamino)ethyl]-3,5-dimethylpyrazole
• 英文别名: 2-(3,5-Dimethyl-1H-pyrazol-1-yl)-N-ethylethan-1-amine；2-(3,5-dimethylpyrazol-1-yl)-N-ethylethanamine
• CAS: 167960-75-0
• 化学式: C₉H₁₇N₃
• mdl: MFCD14655734
• 分子量: 167.254
• InChiKey: AEAWUJQLWSOBHU-UHFFFAOYSA-N

物化性质

• 沸点：
  259.7±28.0 °C(Predicted)
• 密度：
  1.00±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  29.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  cadmium(II) chloride 、 1-[2-(ethylamino)ethyl]-3,5-dimethylpyrazole 在 triethyl orthoformate 作用下， 以 乙醇 为溶剂， 以57%的产率得到dichloro(1-[2-(ethylamino)ethyl]-3,5-dimethylpyrazole)cadmium(II)
  参考文献：
  名称：

  Coordination compounds of Cd(II) with several bidentate-NN′ and tridentate-NN′N nitrogen donor ligands. 113Cd NMR studies of monomeric compounds containing nitrogen donor atoms

  摘要：

  Reaction of CdCl2 with N-alkylaminopyrazole ligands 1-[(2-ethylamino)ethyl]-3,5-dimethylpyrazole (deae), 1-[(2-(tert-butylamino)ethyl)]-3,5-dimethylpyrazole (deat), bis-[(3,5-dimethylpyrazolyl)methyl]ethylamine (bdmae), and bis-[(3,5-dimethylpyrazolyl)ethyl]ethylamine (ddae) in absolute ethanol yields [CdCl2(NN')] (NN' = deae (1), deat (2)), [CdCl2(bdmae)] (3), and [CdCl(ddae)](2)[CdCl4] (4). The Cd(II) complexes have been characterised by elemental analyses, conductivity measurements, IR, H-1, C-13{H-1} and Cd-113 NMR spectroscopies, and X-ray diffraction methods. H-1 and Cd-113 NMR experiments at variable temperature for 3 and 4 show that dynamic processes are taking place in solution. We report the measurements of Cd-113 NMR chemical shift data for complexes 1-4 in solution. X-ray crystal structures for complexes 2 and 3 have been determined. The Cd(II) is coordinated to the deat ligand, in 2, by one nitrogen atom of the pyrazolyl group and one nitrogen atom of the amine. It finishes a tetrahedral geometry with two chlorine atoms. The bdmae ligand is linked to Cd(II), in 3, by two nitrogens atoms of the pyrazolyl groups and one amine nitrogen, along with two chlorine atoms, in a distorted trigonal bipyramidal geometry. (C) 2008 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ica.2008.12.009
• 作为产物：
  描述：

  1-[2-(p-toluenesulfonyloxy)ethyl]pyrazole 、 乙胺 在 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 以81%的产率得到1-[2-(ethylamino)ethyl]-3,5-dimethylpyrazole
  参考文献：
  名称：

  Organometallic rhodium (I) complexes with 1-alkylaminopyrazole ligands

  摘要：

  New bidentate NN ' and tridentate NN 'N 1-alkylaminopyrazoles were synthesized and characterized by elemental analyses and spectroscopic methods. The reaction of [RhCl(cod)(2)] (cod = cycloocta-1,5-diene) with one equivalent of L 1-alkylaminopyrazoles afforded Rh2Cl2(L)(cod)(2) complexes (L = NN ' and NN 'N). These rhodium (I) compounds were studied by IR, H-1- and C-13-NMR and liquid mass (with electrospray and APCI interfaces) spectrometries. The H-1-NMR spectra and molar conductances of these complexes suggested the presence of 1:1 electrolyte species, [Rh(L)cod](+) [RhCl2(cod)](-), in solution. A combined electrospray and APCI liquid mass spectroscopy study confirmed the presence of both [Rh(L)cod](+) and [RhCl2(cod)](-) species in solution bur the existence of a neutral molecular form of complexes in solution could not be demonstrated. (C) 2001 Elsevier Science B.V. All rights reserved.

  DOI：

  10.1016/s0022-328x(00)00662-8

文献信息

• Synthesis of a New Potentially Hemilabile Ligand: 1-[2-(Diphenylphosphanyl)ethyl]-3,5-dimethylpyrazole, and Comparison of Its Bonding Properties with the Related 1-[2-(Ethylamino)ethyl]-3,5-dimethylpyrazole Ligand toward RhI
  作者：Glòria Esquius、Josefina Pons、Ramón Yáñez、Josep Ros、René Mathieu、Bruno Donnadieu、Noël Lugan

  DOI：10.1002/1099-0682(200211)2002:11<2999::aid-ejic2999>3.0.co;2-a

  日期：2002.11

  5-dimethylpyrazole (2) has been prepared by the reaction of 1-(chloroethyl)-3,5-dimethylpyrazole and PPh2Li. The bidentate N,N ligand 1-[2-(ethylamino)ethyl]-3,5-dimethylpyrazole (1) and 2 react with [Rh(COD)(THF)2][BF4] to give [Rh(COD)(1)][BF4] (3) and [Rh(COD)(2)][BF4] (4), respectively. Substitution of 1,5-cyclooctadiene with carbon monoxide in the latter complexes generates [Rh(CO)2(1)][BF4] (5) and

  通过1-(氯乙基)-3,5-二甲基吡唑与PPh2Li反应制备了新的配体1-[2-(二苯基膦酰基)乙基]-3,5-二甲基吡唑(2)。双齿 N,N 配体 1-[2-(乙基氨基)乙基]-3,5-二甲基吡唑 (1) 和 2 与 [Rh(COD)(THF)2][BF4] 反应生成 [Rh(COD)( 1)][BF4] (3) 和 [Rh(COD)(2)][BF4] (4)，分别。在后一种复合物中用一氧化碳取代 1,5-环辛二烯生成 [Rh(CO)2(1)][BF4] (5) 和
• Coordination compounds of a didentate pyrazole-containing ligand. Spectroscopic analyses and crystal structures of bis-[chloro-μ-chloro-{N,N′-(2-(3,5-dimethyl-1-pyrozolyl)ethyl)ethylamine}nickel(II)] [trichloro-{N-(2-(3,5-dimethyl-1-pyrozolyl)ethyl)hydrolammonium}copper(II)]
  作者：Willem L. Driessen、Renate M. de Vos、Anke Etz、Jan Reedijk

  DOI：10.1016/0020-1693(95)90053-9

  日期：1995.7

  and Z = 8. The R value is 0.046 (Rw = 0.046) for 2230 significant reflections. This dinuclear compound is centrosymmetric, with the two nickel(II) ions separated by 3.6059(9) A. Each Ni(II) ion is in a distorted trigonal bipyramidal N2Cl3 environment of two bridging chloride ions at 2.458(1) and 2.351(1) A, an amine and a pyrazole nitrogen of dae at 2.022(3) and 2.036(3) A, and a third chloride ion at

  配体（2-（3,5-二甲基-1-吡唑基）乙基）乙胺（dae）通过吡唑和化合物[Co（dae）Cl2]，[Co（dae ）（NCS）2]·2 ，[Ni（dae）Cl2] 2，[Cu（dae）（NO3）2]·H2O，[Cu（dae）F]（BF4）· ，[Zn（dae）Cl2 ]和[Zn（dae）（NCS）2]·2 。在[Cu（daeH）Cl3]中，配体dae在胺氮上质子化，并通过吡唑氮与铜（II）离子配位。如光谱分析所示，阴离子参与所有化合物中金属离子的配位。金属离子是四，五或六配位的，取决于特定的阳离子-阴离子组合。化合物[Ni（dae）Cl2] 2在正交空间群Pbcn中结晶，a = 13.3466（5），b = 10.7977（5），c = 18.1993（15）A，Z = 8.R值为0.046（ Rw = 0。046）进行2230次重大反射。此双核化合物是中心对称的，两个镍（II）离子之间的距离为3
• Synthesis of new platinum(II) compounds with several bidentate and tridentate nitrogen-donor ligands. Structural analyses by 1H, 13C{1H} and 195Pt{1H} NMR spectroscopy and X-ray crystal structure
  作者：M. del Carme Castellano、Josefina Pons、Jordi García-Antón、Xavier Solans、Mercè Font-Bardia、Josep Ros

  DOI：10.1016/j.ica.2008.01.016

  日期：2008.6

  The reaction of the N -alkylaminopyrazole ( NN ′) ligands 1-[2-(ethylamino)ethyl]-3,5-dimethylpyrazole (deae), 1-[2-( tert -butylamino)ethyl]-3,5-dimethylpyrazole (deat), or ( NN ′ N ) ligands bis[(3,5-dimethylpyrazolyl)methyl]ethylamine (bdmae) and bis[(3,5-dimethylpyrazolyl)ethyl]ethylamine (ddae) with [PtCl 2 (CH 3 CN) 2 ] affords a series of square-planar Pt(II) complexes with formula [PtCl 2 (

  N-烷基氨基吡唑（NN'）配体1- [2-（乙基氨基）乙基] -3,5-二甲基吡唑（deae），1- [2-（叔丁基氨基）乙基] -3,5-二甲基吡唑的反应（deat）或（NN'N）配体，双[[（3,5-二甲基吡唑基）甲基]乙胺（bdmae）和双[（3,5-二甲基吡唑基）乙基]乙胺（ddae）与[PtCl 2（CH 3 CN） ）2]提供了一系列具有式[PtCl 2（NN'）]（NN'= deae（1）; deat（2）），[PtCl 2（bdmae）]（3）的方形Pt（II）配合物，或[PtCl（ddae）] Cl（4）。在CH 2 Cl 2 /甲醇（3：1）中存在AgBF 4的情况下处理复合物4，得到[PtCl（ddae）]（BF 4）（5）。这些Pt（II）配合物已通过元素分析，电导率测量和IR，1 H，13 C 1 H}和195 Pt 1 H} NMR光谱进行了表征。配合物的1
• PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Genentech, Inc.

  公开号：US20130225557A1

  公开（公告）日：2013-08-29

  Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I化合物包括立体异构体、几何异构体、互变异构体、代谢产物和药学上可接受的盐，可用于抑制PI3K的δ异构体，并用于治疗由脂质激酶介导的炎症、免疫性疾病和癌症等疾病。揭示了使用公式I化合物进行哺乳动物细胞中的体外、原位和体内诊断、预防或治疗此类疾病或相关病理条件的方法。
• BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE
  申请人：Castanedo Georgette

  公开号：US20100305084A1

  公开（公告）日：2010-12-02

  Formula I (Ia and Ib) compounds wherein (i) X 1 is N and X 2 is S, (ii) X 1 is CR 7 and X 2 is S, (iii) X 1 is N and X 2 is NR 2 , (iv) X 1 is CR 7 and X 2 is O, or (v) X 1 is CR 7 and X 2 is NR 2 , including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I（Ia和Ib）化合物，其中（i）X1为N且X2为S，（ii）X1为CR7且X2为S，（iii）X1为N且X2为NR2，（iv）X1为CR7且X2为O，或（v）X1为CR7且X2为NR2，包括立体异构体，互变异构体，代谢物和药学上可接受的盐，对于抑制PI3K的δ亚型以及治疗由脂质激酶介导的疾病（如炎症，免疫和癌症）有用。公开了使用公式I化合物的方法，用于哺乳动物细胞中的体外，体内和原位诊断，预防或治疗此类疾病或相关病理条件。